Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
Eggermont, Alexander M M; Blank, Christian U; Mandala, Mario; Long, Georgina V; Atkinson, Victoria; Dalle, Stéphane; Haydon, Andrew; Lichinitser, Mikhail; Khattak, Adnan; Carlino, Matteo S; Sandhu, Shahneen; Larkin, James; Puig, Susana; Ascierto, Paolo A; Rutkowski, Piotr; Schadendorf, Dirk; Koornstra, Rutger; Hernandez-Aya, Leonel; Maio, Michele; van den Eertwegh, Alfonsus J M; Grob, Jean-Jacques; Gutzmer, Ralf; Jamal, Rahima; Lorigan, Paul; Ibrahim, Nageatte; Marreaud, Sandrine; van Akkooi, Alexander C J; Suciu, Stefan; Robert, Caroline.
N Engl J Med
; 378(19): 1789-1801, 2018 May 10.
Artigo em Inglês | MEDLINE | ID: mdl-29658430
PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.
Interferon alpha for the adjuvant treatment of cutaneous melanoma.
Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.
PD-L1 expression and survival among melanoma patients treated with standard immunotherapy or chemotherapy.
VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival.
Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma.
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
Surgical excision margins for primary cutaneous melanoma.
Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.
[Expression and prognostic values of PD-1, PD-L1 and IDO-1 in sinonasal malignant mucosal melanoma].